You just read:

Although Enbrel Will Remain Surveyed Dermatologists' Most-Prescribed First-Line Biologic for Psoriasis, It Will Lose Market Share in This Line to the Il-12/Il-23 Inhibitors

News provided by

Decision Resources

Dec 01, 2010, 08:00 EST